Drug-Induced Liver Injury (DILI) Network Retrospective (ILIAD)

Idiosyncratic Liver Injury Associated With Drugs (ILIAD): A Retrospective Study

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies.

A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.

Study Overview

• Status: Recruiting
• Conditions: Drug Induced Liver Injury

Detailed Description

Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate research into DILI, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently established the Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with any drugs (ILIAD) and HDS agents, and to collect, immortalize and store serum, DNA, and lymphocytes from these patients (hereafter referred to as the "ILIAD protocol"). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the basis for susceptibility to severe idiosyncratic DILI.

The network will initially identify people who have developed DILI onset beyond 6 months of enrollment due to all drugs or HDS/CAM cases that did not meet the entrance criteria for the Prospective study.

The specific aims are as follows:

1. Establish and maintain a clinical database of these people that contains relevant clinical data.
2. Establish a bank of biological specimens (serum, DNA, and immortalized lymphocytes) prepared from cases and control in the clinical database.
3. Maintain a registry including yearly updated contact information of the subjects enrolled in the clinical database so that it is possible to recontact these individuals at a later date to offer participation in studies which are not part of the current proposal.

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Matt Baum; Phone Number: 919-668-0486; Email: matt.baum@duke.edu
• Study Contact Backup: Name: Eilene Pham; Phone Number: 919-660-7253; Email: eilene.pham@duke.edu

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • Recruiting
      • University of Southen California
      • Principal Investigator: Andrew Stolz, MD
      • Contact: Susan Milstein, RN; Phone Number: 323-442-2699; Email: smilstei@usc.edu
      • Contact: Neil Kaplowitz, MD; Phone Number: 323-442-5576; Email: kaplowit@usc.edu
  • Indiana
    • Indianapolis, Indiana, United States, 46202-5111
      • Recruiting
      • Indiana University
      • Principal Investigator: Naga P Chalasani, MD
      • Contact: Jennifer Terrell; Phone Number: 317-278-6266; Email: jkramey@iu.edu
  • Maryland
    • Bethesda, Maryland, United States, 20892
      • Recruiting
      • NIH Clinical Site
      • Contact: Chris Koh, MD; Email: christopher.koh@nih.gov
      • Contact: Jaha Norman-Wheeler; Phone Number: 301-435-6122; Email: jaha.norman-wheeler@nih.gov
  • Michigan
    • Ann Arbor, Michigan, United States, 48109-0362
      • Recruiting
      • University of Michigan
      • Principal Investigator: Robert J Fontana, MD
      • Contact: Josefa Kaganove; Email: kaganovj@med.umich.edu
  • New York
    • New York, New York, United States, 10029
      • Active, not recruiting
      • Icahn School of Medicine at Mount Sinai
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599-7600
      • Recruiting
      • Univeristy of North Carolina at Chapel Hill
      • Principal Investigator: Paul B Watkins, MD
      • Contact: Jacquee Simpson; Email: Jacqueline_Simpson@med.unc.edu
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19141
      • Recruiting
      • Thomas Jefferson
      • Contact: Katrin Koy; Phone Number: 215-456-2004; Email: koykatri@einstein.edu
      • Principal Investigator: Dima Halegoua-DeMarzio, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with liver injury ascribed to any drug or HDS/CAM agent which the DILI onset date occurred beyond six months from enrollment.

Description

Inclusion Criteria:

Screening Criteria

To be included in the ILIAD registry, the following criteria must be satisfied:

• The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury;
• The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;
• Evidence of injury that is known or suspected to be related to consumption of a drug or HDS/CAM product
• The subject is taking only one of these drugs or HDS agent(s) in the period leading up to the onset of the qualifying DILI episode;
• Have clinically important DILI defined in terms of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (Alk Phos).
• Sufficient documentation of the event for the Causality Committee to make a determination.

Exclusion Criteria:

Subjects will be excluded according to the following criteria:

• are not willing to have medical information and blood samples taken;
• are unable to adequately give informed consent to participate in the study including the blood draw for the genetic component;
• age < 2 years old at the time of study enrollment (due to blood volume requirements).
• Have a competing cause of liver injury such as hepatic ischemia that the investigator felt to be the primary reason for the observed liver injury. Known, pre-existing autoimmune hepatitis; primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease. Subjects are excluded due to acetaminophen hepatoxicity or liver transplant or allogeneic bone marrow transplant prior to development of drug-CAM induced liver injury.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Subjects with liver injury
Subjects without liver injury

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
maintain a registry of cases in the ILIAD database	maintain a registry of cases in the ILIAD database	July 2028

Collaborators and Investigators

• Sponsor: Duke University
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Investigators: Principal Investigator: Huiman X. Barnhart, PhD, Duke University; Study Chair: Robert Fontana, MD, University of Michigan

Publications and helpful links

General Publications

• Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008 Oct;48(4):1175-83. doi: 10.1002/hep.22442.

Helpful Links

• The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is part of the National Institutes of Health (NIH)
• Multi-center, Longitudinal Study of Drug-and-CAM-Induced Liver Injury

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2004
• Primary Completion (Estimated): July 31, 2028
• Study Completion (Estimated): July 31, 2028

Study Registration Dates

• First Submitted: August 2, 2006
• First Submitted That Met QC Criteria: August 2, 2006
• First Posted (Estimated): August 4, 2006

Study Record Updates

• Last Update Posted (Actual): April 3, 2024
• Last Update Submitted That Met QC Criteria: April 2, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: phenotype; genotype; Drugs; LIVER DIS; CHEM IND; Drug induced liver injury; cholestatic liver injury; hepatocellular liver injury; mixed liver injury
• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Digestive System Diseases; Liver Diseases; Drug-Related Side Effects and Adverse Reactions; Poisoning; Wounds and Injuries; Chemical and Drug Induced Liver Injury
• Other Study ID Numbers: Pro00113362; Pro00017208 (Other Identifier: Original Duke IRB number); 2U01DK065176-21 (U.S. NIH Grant/Contract); Pro00072297 (Other Identifier: Advarra)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No